Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
Conditions
- Intracerebral Haemorrhage (ICH)
- Hypertension
Interventions
- DRUG: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
- DRUG: Placebo
Sponsor
The George Institute
Collaborators